Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?

The Archetypal Orphan Drug Biotech Company Remains Loss-Making

Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.

StockWatch_Andy-Smith_V1_1200.jpg
ANDY SMITH GIVES A LIFE SCIENCES INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

More from R&D

More from Scrip